Thursday - July 30, 2026
FDA Center for Drug Evaluation & Research Issues Warning Letter to FitRX
March 04, 2026
WASHINGTON, March 4 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to FitRX LLC from its Center for Drug Evaluation and Research:

* * *

Recipient: FitRX, LLC dba FitRx, 30 Irving Pl, New York, NY 10003, United States, support@fitrxapp.com

Issuing Office: Center for Drug Evaluation and Research (CDER), United States

WARNING LETTER

FitRx:

This letter . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products